Key result
Early identification and population-level screening for chronic kidney disease can decrease the global burden of kidney disease, though significant barriers to implementation remain.
Answers are grounded in this paper and cite their sources.
Advocates for early detection and screening of chronic kidney disease to prevent progression and cardiovascular complications, highlighting the cost-benefit of new treatments like SGLT2 inhibitors.
Early identification of kidney disease can protect kidney health, prevent kidney disease progression and related complications, reduce cardiovascular disease (CVD) risk and decrease mortality. We must ask 'Are your kidneys ok?' using serum creatinine to estimate kidney function and urine albumin to assess for kidney and endothelial damage. Evaluation for causes and risk factors for chronic kidney disease (CKD) includes testing for diabetes and measurement of blood pressure and body mass index. This World Kidney Day, we assert that case-finding in high-risk populations, or even population-level screening, can decrease the burden of kidney disease globally. Early-stage CKD is asymptomatic, simple to test for and recent paradigm-shifting CKD treatments, such as sodium glucose co-transporter-2 inhibitors, dramatically improve outcomes and favour the cost-benefit analysis for screening or case-finding programmes. Despite this, numerous barriers exist, including resource allocation, healthcare funding, healthcare infrastructure and healthcare-professional and population awareness of kidney disease. Coordinated efforts by major kidney non-governmental organisations to prioritise the kidney health agenda for governments and aligning early detection efforts with other current programmes will maximise efficiencies.
No takes yet. Share an insight, caveat, or question.
Vassalotti et al. (2025) conducted an editorial in Chronic kidney disease (CKD). Early detection and screening was evaluated. Early identification and population-level screening for chronic kidney disease can decrease the global burden of kidney disease, though significant barriers to implementation remain.
Synapse has enriched 10 related papers. Consider them for comparative context: